Expertise in
105
conditions

Dr. Mohammad M. Jamal

Gastroenterology
Gastroenter
2097 Compton Ave, 
Corona, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
105
conditions
Gastroenter
2097 Compton Ave, 
Corona, CA 

Overview

Mohammad Jamal is a Gastroenterologist practicing medicine in Corona, California.

Dr. Jamal is highly rated in 105 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Diverticular Disease, Gastrointestinal Bleeding, Endoscopy, and Colonoscopy.

Dr. Jamal is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 7 clinical trials. Dr. Jamal is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in NV

Board Certifications

American Board Of Internal Medicine

Fellowships

University of New Mexico Medical School , 1990 - 1991

Hospital Affiliations

Corona Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Gastroenter
2097 Compton Ave, Corona, CA 92881
Other Locations
Basim Z. Abdelkarim, M.d., Inc.
1310 San Bernardino Rd, Upland, CA 91786

Additional Areas of Focus

Dr. Jamal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Enrollment Status: Completed
Publish Date: February 11, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
Enrollment Status: Completed
Publish Date: April 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

4 Total Publications

Mirizzi-Induced Bouveret's Syndrome: Revelations of Timely Surgical Intervention.
Mirizzi-Induced Bouveret's Syndrome: Revelations of Timely Surgical Intervention.
Journal: Case reports in gastroenterology
Published: September 27, 2021
Similar Doctors
Expertise in
52
conditions
Dr. Tarek I. Hassanein
Gastroenterology
Expertise in
52
conditions
Dr. Tarek I. Hassanein
Gastroenterology
Referral required
Before you request
27700 Medical Center Road, 
Mission Viejo, CA 
 (21.2 miles away)
949-364-1400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tarek Hassanein is a Gastroenterologist practicing medicine in Mission Viejo, California. Dr. Hassanein is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Non-Alcoholic Fatty Liver Disease, Endoscopy, and Liver Transplant. Dr. Hassanein is board certified in American Board Of Internal Medicine. Dr. Hassanein is currently accepting new patients.

Expertise in
23
conditions
Dr. Norah A. Terrault
Gastroenterology
Expertise in
23
conditions
Dr. Norah A. Terrault
Gastroenterology
Referral may be required

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (41.2 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Norah Terrault is a Gastroenterologist practicing medicine in Los Angeles, California. Dr. Terrault is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Expertise in
49
conditions
Dr. Jason B. Samarasena
Gastroenterology
Expertise in
49
conditions
Dr. Jason B. Samarasena
Gastroenterology
Referral may be required

UCI Health Chao Family Comprehensive Digestive Disease Center

101 The City Drive South, Building 22C, 
Orange, CA 
 (20.8 miles away)
888-717-4463
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Jason Samarasena is a UCI Health physician who specializes in treating gastrointestinal disorders, including gastroesophageal reflux disease, esophageal disease, pancreatic cysts, biliary tract disorders, gastric intestinal metaplasia and colorectal cancer.His research interests include advanced endoscopic imaging, characterization and treatment of pancreatic cysts, confocal laser endomicroscopy, bowel preparation before colonoscopy, endoscopic mucosal resection and endoscopic submucosal dissection.Samarasena received his medical degree from Memorial University of Newfoundland, Canada, where he graduated on the Dean’s List. He completed both general gastroenterology and interventional endoscopy fellowships at UC Irvine.Press Ganey has named Samarasena as one of the top five physicians for patient satisfaction in the ambulatory surgery group at UCI Health. He was named the 2016 Teaching Attending of the Year by the UC Irvine Gastroenterology Fellowship. He is the current president of the Orange County GI Society.Nickname: Dr. Sam. Dr. Samarasena is highly rated in 49 conditions, according to our data. His clinical expertise encompasses Barrett Esophagus, Jaundice, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy. Dr. Samarasena is board certified in American Board Of Internal Medicine - Gastroenterology.

Frequently Asked Questions about Dr. Mohammad M. Jamal

How do I make an appointment with Dr. Mohammad M. Jamal?

You can book an appointment with Dr. Mohammad M. Jamal by calling their office at 951-934-0505. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mohammad M. Jamal a top-rated expert for Gastroesophageal Reflux Disease (GERD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohammad M. Jamal is classified as an Distinguished expert for Gastroesophageal Reflux Disease (GERD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohammad M. Jamal specialize in?

While Dr. Mohammad M. Jamal is a Gastroenterology, they have specific expertise in Gastroesophageal Reflux Disease (GERD), Diverticular Disease, and Gastrointestinal Bleeding. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Mohammad M. Jamal participate in research or clinical trials?

Yes. Dr. Mohammad M. Jamal has published 4 articles and abstracts on conditions like Gastroesophageal Reflux Disease (GERD). You can view a list of Dr. Mohammad M. Jamal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mohammad M. Jamal accept my insurance?

Dr. Mohammad M. Jamal accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 951-934-0505 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jamal's expertise for a condition
ConditionClose
    View All 35 Distinguished Conditions
    View All 70 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile